TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32358640
Drug: Probiotic (AminoAlta™,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (AminoAlta™, a multi-strain probiotic with 5 billion CFU L. paracasei LP-DG® and 5 billion CFU L. paracasei LPC-S01)
Study: 35666289
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg (continuous usage)
Study: 35666289
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg (on-demand usage)
Study: 34242498
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen (NBO) at 8 L/min
Study: 32255318
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of nephrotoxic agents
Study: 35668503
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with nicotine patch
Study: 35668503
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with sham nicotine patch
Study: 35668503
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture combined with nicotine patch
Study: 35668503
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture combined with sham nicotine patch
Study: 35789530
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification combined with TEAS four times weekly for 12 weeks
Study: 33832145
Drug: Both PRF
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both PRF stimulation and physical therapy
Study: 33789009
Drug: Sotatercept 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept 0.3 mg/kg every 3 weeks
Study: 33789009
Drug: Sotatercept 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept 0.7 mg/kg every 3 weeks
Study: 32331034
Drug: Pimavanserin (PIM)
DrugBank: Pimavanserin (DB05316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimavanserin (PIM) 34 mg/day
Study: 36175968
Drug: Low-dose titrated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose titrated morphine hydrochloride administered intravenously for 24 hours
Study: 36175968
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl) administered for 24 hours
Study: 33371126
Drug: Basic western
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic western medicine treatment
Study: 33339609
Drug: Alfacalcidol 2
Normalized name: Alfacalcidol 250 nanogram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 2 μg/d started 48 hours before surgery and continued throughout the hospital stay
Study: 33339609
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no alfacalcidol treatment)
Study: 32223112
Drug: Apixaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (10 mg twice daily for the first 7 days, followed by 5 mg twice daily)
Study: 32223112
Drug: Dalteparin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (200 IU per kilogram once daily for the first month, followed by 150 IU per kilogram once daily)
Study: 34402789
Drug: Chemi Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemi Enoxaparin (80 mg/0.8 mL)
Study: 34402789
Drug: Clexane (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clexane (80 mg/0.8 mL)
Study: 35869734
Drug: Clostridium butyricum
Normalized name: Clostridium butyricum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridium butyricum capsules combined with rosuvastatin
Study: 36207156
Drug: Aqua Maris
Normalized name: Aqua Maris
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua Maris Extra Strong irrigation therapy in addition to standard therapy
Study: 36207156
Drug: Aqua Maris
Normalized name: Aqua Maris
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua Maris Extra Strong irrigation therapy
Study: 33761717
Drug: Combined music
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined music therapy + Tai Chi
Study: 33761717
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy alone
Study: 32383801
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention (medication reconciliation at discharge with a link to the community pharmacist)
Study: 34772399
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of erythropoietin (EPO) 4000 IU/ml for 2 minutes before graft placement
Study: 34772399
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of erythropoietin (EPO) 4000 IU/ml
Study: 34600629
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (subsymptom threshold), at least 20 min daily for up to 4 weeks
Study: 34600629
Drug: Stretching exercise
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching exercise (placebo-like), at least 20 min daily for up to 4 weeks
Study: 34214220
Drug: Fractional radiofrequency
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional radiofrequency microneedling monotherapy (group B)
Study: 33221326
Drug: Abicipar 2
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar 2 mg every 8 weeks (abicipar Q8, n=630)
Study: 33221326
Drug: Abicipar 2
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar 2 mg every 12 weeks (abicipar Q12, n=628)
Study: 33221326
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg every 4 weeks (ranibizumab Q4, n=630)
Study: 34920097
Drug: OC‐01 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC‐01 0.03 mg
Study: 34920097
Drug: OC‐01 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC‐01 0.06 mg
Study: 32598243
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous (i.v.) antibiotic
Study: 32598243
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic + additional dose i.v. antibiotic
Study: 32598243
Drug: Prophylaxis +
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis + additional dose i.v. antibiotic + oral antibiotic
Study: 33539750
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy
Study: 33539750
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of pertuzumab and trastuzumab
Study: 35045735
Drug: 8 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 sessions of weekly, individualized, lifestyle education (diet and PA) with behavior change and social support delivered predominantly by telehealth.
Study: 32869593
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (levofloxacin eye drops and gel)
Study: 34739194
Drug: Daprodustat (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat (oral HIF-PHI)
Study: 33040811
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three orthodontic treatments
Study: 36201240
Drug: Nabilone (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (1-2 mg, oral)
Study: 33727311
Drug: Escalation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation of therapy in 94 patients
Study: 36175997
Drug: green‐MED diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: green‐MED diet (100 g frozen cubes/day of Wolffia globosa, 3-4 cups/day of green tea, 28 g/day of walnuts)
Study: 36175997
Drug: MED diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MED diet (28 g/day of walnuts)
Study: 32228720
Drug: Internal TCM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal TCM treatment for mild-to-moderate plaque psoriasis
Study: 32228720
Drug: External TCM
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: External TCM treatment for mild-to-moderate plaque psoriasis
Study: 32228720
Drug: TCM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM treatment for severe plaque psoriasis
Study: 32228720
Drug: WM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: WM treatment for severe plaque psoriasis
Study: 32228720
Drug: TCM +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCM + WM treatment for severe plaque psoriasis
Study: 36412412
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400 mcg given 3 hours prior to the procedure
Study: 32391881
Drug: Adjunctive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive oral cannabidiol
Study: 35264510
Drug: Palatal brushing
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palatal brushing and standard oral/denture hygiene
Study: 35264510
Drug: Standard oral/denture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral/denture hygiene instructions only
Study: 32964717
Drug: Furosemide (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (0.2 to 0.5 mg/kg as a continuous intravenous infusion for 24 hours postoperatively)
Study: 32964717
Drug: Furosemide combined
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide combined with standard hydration therapy
Study: 32962709
Drug: CHF6001 400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 400, 800, 1200 or 1600 μg twice daily (BID)
Study: 32962709
Drug: CHF6001 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 800 and 1600 μg BID
Study: 34936167
Drug: Vaporized cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized cannabis containing 13.75 mg THC
Study: 32115392
Drug: Medication education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication education and management
Study: 32115392
Drug: Non‐medication‐related patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐medication‐related patient education
Study: 33459183
Drug: Adaptive design
Normalized name: Designer Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive design integrating dose finding and confirmation steps
Study: 34559230
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of FRM-0334
Study: 34559230
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of FRM-0334
Study: 34559230
Drug: FRM-0334 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRM-0334 (both doses)
Study: 34985771
Drug: Online intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online intervention supporting couples' posttreatment recovery of sexual intimacy, comprising 6 modules addressing expectations for sexual and emotional sequelae of treatment, rehabilitation, and guidance toward sexual intimacy recovery.
Study: 32783330
Drug: Topical PR
Normalized name: Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical PR gel under the left orbit once a day and topical plus nano‐microneedle‐assisted PR gel under the right orbit twice a week
Study: 32783330
Drug: Gel without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel without PR (Control)
Study: 34427049
Drug: ASP5354 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP5354 0.1 mg
Study: 34427049
Drug: ASP5354 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP5354 (0.1 mg to 24 mg)
Study: 33484515
Drug: Core stability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core stability exercises along with traditional therapy
Study: 33484515
Drug: Traditional low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional low backache physical therapy
Study: 34138468
Drug: Intravenous polyspecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous polyspecific immunoglobulin G (IVIG) 25 g/d for 3 days
Study: 33225782
Drug: Isosorbide‐5‐mononitrate capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate capsule
Study: 35965813
Drug: Zengxiao Jiandu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zengxiao Jiandu decoction combined with definitive concurrent chemoradiotherapy (DCCRT)
Study: 32561468
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 IU) administered prior to each PE therapy session
Study: 32561468
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered prior to each PE therapy session
Study: 36421994
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Whole PT and SupB (A+SupB)
Study: 32220355
Drug: Curcumin 500
Normalized name: curcumin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 500 mg/day for 12 weeks
Study: 33729546
Drug: FOLFOX (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (all three agents)
Study: 34126156
Drug: REGN5713/14/15 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN5713/14/15 (900 mg)
Study: 33394214
Drug: Lansoprazole (LAN)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LAN) 60 mg p.o. bid for one week before starting each cycle + R‐CHOP
Study: 33394214
Drug: Famotidine (FAM)
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine (FAM) 40 mg p.o. once daily one week before cycle and continues daily through the cycle + R‐CHOP for six cycles
Study: 33394214
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received R‐CHOP standard chemotherapy
Study: 35690876
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (standard model of care delivered by the Justice Health and Forensic Mental Health Network)
Study: 32267847
Drug: First-line antiretroviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line antiretroviral therapy
Study: 35292944
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (80 mg) and calcium (1 g) daily
Study: 36301511
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine (20 mg/kg)
Study: 36301511
Drug: Enteral caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral caffeine (20 mg/kg)
Study: 33277284
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine
Study: 32469385
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg/d for 36 months
Study: 32469385
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg/d for 12 months
Study: 35193873
Drug: MTX-hold (2-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-hold (2-week methotrexate discontinuation after each vaccine dose)
Study: 35639672
Drug: LifeBuoy (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: LifeBuoy (therapeutic smartphone application based on dialectical behavior therapy)
Study: 32499466
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 1.2 g amoxicillin‐clavulanic acid
Study: 32499466
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days course of amoxicillin‐clavulanic acid and metronidazole
Study: 34635373
Drug: Currently licensed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Currently licensed MenACWY-CRM vaccine presentation
Study: 35149125
Drug: Peg‐IFN‐α‐based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN‐α‐based therapy for 96 weeks with 24-week off-treatment follow-up
Study: 35149125
Drug: Peg‐IFN‐α‐based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN‐α‐based therapy
Study: 35149125
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HBcrAg <4 log10U/ml and HBsAb >2 log10IU/L at EOT
Study: 34960153
Drug: Revaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccination with one dose of hepatitis B vaccine containing 60 µg HBsAg
Study: 34960153
Drug: Revaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccination with one dose of hepatitis B vaccine containing 20 µg HBsAg
Study: 34791503
Drug: Peer-led oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-led oral health intervention based on Health Belief Model and Social Cognitive Theory
Study: 33678183
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml ABHR volume
Study: 33678183
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml ABHR volume
Study: 33678183
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml ABHR volume
Study: 33678183
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml ABHR volume
Study: 33678183
Drug: 3.5 ml
Normalized name: ethanol 3.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 ml or more ABHR volume
Study: 35888587
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation treatment (2 sessions per day for 90 min, 5 days a week)
Study: 32702190
Drug: Studies for
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Studies for first-line therapy
Study: 35410967
Drug: Prednisolone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (15 mg/m2 daily for 6 days)
Study: 33590829
Drug: Upadacitinib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (15 mg QD)
Study: 33371023
Drug: Physitrack online
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physitrack online exercise prescription tool
Study: 35526026
Drug: Tanreqing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanreqing oral liquid, 20 mL three times daily for seven consecutive days
Study: 35526026
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral liquid, 20 mL three times daily for seven consecutive days
Study: 35276914
Drug: Lactococcus lactis
Normalized name: Lactococcus Lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactococcus lactis strain Plasma (LC‐Plasma) administered as a beverage (1.0 × 10^11 count LC‐Plasma/day/person)
Study: 33101559
Drug: LED light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED light therapy with electromagnetic field (MLT)
Study: 33612629
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nutrition Education and Multi-Nutrient Biscuits (NE+MNB)
Study: 33023221
Drug: Low Protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Protein (LP) - 15 g protein
Study: 33023221
Drug: Medium Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Protein (MP) - 30 g protein
Study: 33023221
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein (HP) - 45 g protein
Study: 33023221
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - 7 g protein
Study: 33615957
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with cTACE + MWA (Group 3)
Study: 35865817
Drug: Empirical intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical intravenous antibiotic therapy during endotherapy (Group 1)
Study: 35865817
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic therapy during endoscopic drainage (Group 2)
Study: 35578271
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration with a target of 2–2.5 times baseline aPTT
Study: 35578271
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration with a target of 1.5–2 times baseline aPTT
Study: 35578271
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin guided by weight and renal function
Study: 33259725
Drug: Standardized Tinnitus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized Tinnitus Retraining Therapy (TRT)